Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Acute Renal Failure: early-phase trial registry

1 of 6 indexed Acute Renal Failure trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Acute Renal Failure: 6 US clinical trials tracked, 1 recruiting.

Acute Renal Failure is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is University of Texas, running 1 of these trials.

Enrollment posture brief

Registry condition acute-renal-failure

OPEN 1 | RECR 17% | LATE 0 | EARLY 2 | RANK #2866 | SPON 1

Nearest open-share peer: Adherence, Patient (17% recruiting · 12 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Acute Renal Failure (this)17%
Open-enrollment share among volume-matched conditions near Acute Renal Failure

Acute Renal Failure lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Acute Renal Failure on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Acute Renal Failure is recruiting below its size-band peers.

    1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Acute Renal Failure research.

    University of Texas accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Acute Renal Failure trials plan to enrol fewer than 100 people.

    Median target enrolment is 45 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.

  4. Acute Renal Failure research is mostly interventional.

    5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Named interventions

Most-linked intervention names on Acute Renal Failure records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

alpha-melanocyte stimulating hormone Drug
1 trials
Thymoglobulin 0.75mg/kg dose Drug
1 trials
Script and CPR/Mechanical ventilation video. Other
1 trials
MANNITOL Drug
1 trials
Urodilatin (ularitide, Atrial Natriuretic Peptide) Drug
1 trials
Kidney Biopsy Procedure
1 trials
N-acetylcysteine Drug
1 trials
Thymoglobulin Drug
1 trials

US sites by state

Facility locations filed on Acute Renal Failure trials. A trial with sites in several states counts in each.

Texas 3 trials
Ohio 2 trials
Massachusetts 2 trials
Pennsylvania 1 trials
New York 1 trials
Maryland 1 trials
Connecticut 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Acute Renal Failure page

6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Renal Failure condition card totals 6 registered trials; most-linked intervention alpha-melanocyte stimulating hormone; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.